无症状阶段与记忆门诊人群中α-突触核蛋白病理的MRI特征
该横断面研究纳入瑞典BioFINDER-2(发现队列)、BioFINDER-1和ADNI(重复队列)共2961名认知正常或受损个体,发现脑脊液种子扩增检测α-突触核蛋白阳性与胆碱能基底前脑核团(尤其是NBM)体积减小独立相关,且在认知受损者中NBM萎缩部分介导了α-突触核蛋白阳性与注意力/执行功能损害之间的关联。
要点
- 脑脊液α-突触核蛋白种子扩增阳性与NBM及CH1/2/3体积减小独立相关,校正阿尔茨海默病理后仍存在。
- 在认知正常和认知受损亚组中,α-突触核蛋白阳性均与NBM体积减小独立相关。
- 在认知受损者中,NBM体积部分介导α-突触核蛋白阳性与注意力/执行功能损害的关联。
核心结论
- 在队列研究中,脑脊液种子扩增检测α-突触核蛋白阳性在无症状阶段即与NBM萎缩一致相关。
- 在记忆门诊认知受损人群中,α-突触核蛋白阳性与NBM萎缩相关,后者部分介导α-突触核蛋白诱导的注意力/执行功能损害。
研究设计与样本
- 横断面研究,使用瑞典BioFINDER-2研究(纳入2017—2023年)作为发现队列,瑞典BioFINDER-1研究(纳入2007—2015年)和阿尔茨海默病神经影像学倡议ADNI(纳入2005—2022年)作为重复队列。
- 所有队列均为多中心研究,但BioFINDER队列使用1台MRI扫描仪;纳入符合标准且相关指标无缺失的认知正常和认知受损个体。
- 共纳入2961名参与者:BioFINDER-2研究1388名(平均[SD]年龄71[10]岁;女性702名[51%]),BioFINDER-1研究752名(平均[SD]年龄72[6]岁;女性406名[54%]),ADNI 821名(平均[SD]年龄75[8]岁;男性449名[55%])。
- 所有分析于2023—2024年进行。
主要发现
- 在BioFINDER-2研究全队列中,基于体素的形态学分析显示种子扩增检测α-突触核蛋白阳性与胆碱能NBM存在特异性关联,即使校正阿尔茨海默共病后仍存在。
- 在BioFINDER-2研究的感兴趣区分析中,种子扩增检测α-突触核蛋白阳性与较小的NBM体积独立相关(β=-0.271;95%CI,-0.399至-0.142;P<.001),与较小的CH1/2/3体积独立相关(β=-0.227;95%CI,-0.377至-0.076;P=.02)。
- 在认知正常亚组中,种子扩增检测α-突触核蛋白阳性与较小的NBM体积独立相关(β=-0.360;95%CI,-0.603至-0.117;P=.03);在认知受损亚组中亦独立相关(β=-0.251;95%CI,-0.408至-0.095;P=.02)。
- 在BioFINDER-1研究和ADNI队列中,种子扩增检测α-突触核蛋白阳性与NBM体积的关联得到重复。
- 在认知受损个体中,NBM体积部分介导种子扩增检测α-突触核蛋白阳性与注意力/执行功能损害的关联:BioFINDER-2研究β=-0.017,中介比例7%,P=.04;BioFINDER-1研究β=-0.096,中介比例19%,P=.04;ADNI β=-0.061,中介比例20%,P=.007。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The lack of an in vivo measure for α-synuclein (α-syn) pathology until recently has limited thorough characterization of its brain atrophy pattern, especially during early disease stages. OBJECTIVE: To assess the association of state-of-the-art cerebrospinal fluid (CSF) seed amplification assays (SAA) α-syn positivity (SAA α-syn+) with magnetic resonance imaging (MRI) structural measures, across the continuum from clinically unimpaired (CU) to cognitively impaired (CI) individuals, in 3 independent cohorts, and separately in CU and CI individuals, the latter reflecting a memory clinic population. DESIGN, SETTING, AND PARTICIPANTS: Cross-sectional data were used from the Swedish BioFINDER-2 study (inclusion, 2017-2023) as the discovery cohort and the Swedish BioFINDER-1 study (inclusion, 2007-2015) and Alzheimer's Disease Neuroimaging Initiative (ADNI; inclusion 2005-2022) as replication cohorts. All cohorts are from multicenter studies, but the BioFINDER cohorts used 1 MRI scanner. CU and CI individuals fulfilling inclusion criteria and without missing data points in relevant metrics were included in the study. All analyses were performed from 2023 to 2024. EXPOSURES: Presence of α-syn pathology, estimated by baseline CSF SAA α-syn. MAIN OUTCOMES AND MEASURES: The primary outcomes were cross-sectional structural MRI measures either through voxel-based morphometry (VBM) or regions of interest (ROI) including an automated pipeline for cholinergic basal forebrain nuclei CH4/4p (nucleus basalis of Meynert [NBM]) and CH1/2/3. Secondary outcomes were domain-specific cross-sectional cognitive measures. Analyses were adjusted for CSF biomarkers of Alzheimer pathology. RESULTS: A total of 2961 participants were included in this study: 1388 (mean [SD] age, 71 [10] years; 702 female [51%]) from the BioFINDER-2 study, 752 (mean [SD] age, 72 [6] years; 406 female [54%]) from the BioFINDER-1 study, and 821 (mean [SD] age, 75 [8] years; 449 male [55%]) from ADNI. In the BioFINDER-2 study, VBM analyses in the whole cohort revealed a specific association between SAA α-syn+ and the cholinergic NBM, even when adjusting for Alzheimer copathology. ROI-based analyses in the BioFINDER-2 study focused on regions involved in the cholinergic system and confirmed that SAA α-syn+ was indeed independently associated with smaller NBM (β = -0.271; 95% CI, -0.399 to -0.142; P <.001) and CH1/2/3 volumes (β = -0.227; 95% CI, -0.377 to -0.076; P =.02). SAA α-syn+ was also independently associated with smaller NBM volumes in the separate CU (β = -0.360; 95% CI, -0.603 to -0.117; P =.03) and CI (β = -0.251; 95% CI, -0.408 to -0.095; P =.02) groups. Overall, the association between SAA α-syn+ and NBM volume was replicated in the BioFINDER-1 study and ADNI cohort. In CI individuals, NBM volumes partially mediated the association of SAA α-syn+ with attention/executive impairments in all cohorts (BioFINDER-2, β = -0.017; proportion-mediated effect, 7%; P =.04; BioFINDER-1, β = -0.096; proportion-mediated effect, 19%; P =.04; ADNI, β = -0.061; proportion-mediated effect, 20%; P =.007). CONCLUSIONS AND RELEVANCE: In this cohort study, SAA α-syn+ was consistently associated with NBM atrophy already during asymptomatic stages. Further, in memory clinic CI populations, SAA α-syn+ was associated with NBM atrophy, which partially mediated α-syn-induced attention/executive impairment.
引用
- Wisse LEM, Spotorno N, Rossi M, et al. MRI Signature of α-Synuclein Pathology in Asymptomatic Stages and a Memory Clinic Population. JAMA Neurol. 2024. PMID: 39068668. doi:10.1001/jamaneurol.2024.2713
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。